Gunderson Dettmer Represents The Column Group in Surrozen’s $175 Million Oversubscribed Private Placement

Gunderson Dettmer represented client The Column Group as an investor in Surrozen’s $175 million oversubscribed private placement. This new financing will help Surrozen (Nasdaq: SRZN), a biotechnology company pioneering Wnt pathway-based therapeutics, to advance its pipeline programs to provide new or improved treatment options for multiple severe and disabling eye diseases.

The Gunderson deal team was led by public companies partner Keith Scherer and senior associate John Maciejewski.

Companies
The Column Group
Surrozen